Literature DB >> 34874461

[Medicinal treatment of retroperitoneal soft tissue sarcomas].

Johanna Falkenhorst1, Rainer Hamacher1, Sebastian Bauer2.   

Abstract

Retroperitoneal soft tissue sarcomas represent extreme challenges for interdisciplinary treatment teams. The sarcoma-specific experience of surgeons has the greatest impact on the survival of patients; however, too many patients still die despite optimal local treatment. The role of chemotherapy is undisputed only for patients with highly malignant bone sarcomas or rhabdomyosarcomas. For soft tissue sarcomas in adult patients, especially liposarcomas and leiomyosarcomas, the evidence situation is very unsatisfactory. This overview article discusses the complex data situation and controversial aspects that are relevant for current treatment decisions in interdisciplinary treatment teams.
© 2021. The Author(s), under exclusive licence to Springer Medizin Verlag GmbH, ein Teil von Springer Nature.

Entities:  

Keywords:  Chemotherapy; Evidence; Leiomyosarcoma; Liposarcoma; Sarcoma

Mesh:

Year:  2021        PMID: 34874461     DOI: 10.1007/s00104-021-01539-x

Source DB:  PubMed          Journal:  Chirurg        ISSN: 0009-4722            Impact factor:   0.955


  2 in total

1.  Histology-specific nomogram for primary retroperitoneal soft tissue sarcoma.

Authors:  Ilaria Ardoino; Rosalba Miceli; Mattia Berselli; Luigi Mariani; Elia Biganzoli; Marco Fiore; Paola Collini; Silvia Stacchiotti; Paolo Giovanni Casali; Alessandro Gronchi
Journal:  Cancer       Date:  2010-05-15       Impact factor: 6.860

2.  Survival Outcomes Associated With 3 Years vs 1 Year of Adjuvant Imatinib for Patients With High-Risk Gastrointestinal Stromal Tumors: An Analysis of a Randomized Clinical Trial After 10-Year Follow-up.

Authors:  Heikki Joensuu; Mikael Eriksson; Kirsten Sundby Hall; Annette Reichardt; Barbara Hermes; Jochen Schütte; Silke Cameron; Peter Hohenberger; Philipp J Jost; Salah-Eddin Al-Batran; Lars H Lindner; Sebastian Bauer; Eva Wardelmann; Bengt Nilsson; Raija Kallio; Panu Jaakkola; Jouni Junnila; Thor Alvegård; Peter Reichardt
Journal:  JAMA Oncol       Date:  2020-08-01       Impact factor: 31.777

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.